tiletamine hydrochloride has been researched along with Multiple Myeloma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (50.00) | 29.6817 |
| 2010's | 1 (25.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Breborowicz, A; Gantsev, S; Umezawa, K | 1 |
| Anderson, KC; Bobb, K; Carrasco, RD; Cirstea, D; Fabre, C; Gorgun, G; Hideshima, T; Hu, Y; Kong, SY; Meshulam, J; Mimura, N; Minami, J; Ohguchi, H; Richardson, PG; Tai, YT; Zhang, J | 1 |
| Dewan, MZ; Higashihara, M; Honda, M; Horie, R; Itoh, K; Mizoguchi, H; Okamura, T; Sasaki, M; Sata, T; Umezawa, K; Watanabe, M; Watanabe, T; Yamamoto, N | 1 |
| Hata, H; Matsuno, F; Mitsuya, H; Nakamura, M; Okuno, Y; Sonoki, T; Taniguchi, I; Tatetsu, H; Umezawa, K; Uneda, S | 1 |
1 review(s) available for tiletamine hydrochloride and Multiple Myeloma
| Article | Year |
|---|---|
Anticancer Activity of Novel NF-kappa B Inhibitor DHMEQ by Intraperitoneal Administration.
Topics: Animals; Antineoplastic Agents; Benzamides; Breast Neoplasms; Cyclohexanones; Female; Humans; Injections, Intraperitoneal; Lymphoma; Male; Mice; Multiple Myeloma; Neoplasms; NF-kappa B | 2020 |
3 other study(ies) available for tiletamine hydrochloride and Multiple Myeloma
| Article | Year |
|---|---|
Dual inhibition of canonical and noncanonical NF-κB pathways demonstrates significant antitumor activities in multiple myeloma.
Topics: Amino Acid Chloromethyl Ketones; Animals; Apoptosis; Boronic Acids; Bortezomib; Cell Differentiation; Cell Line, Tumor; Cyclohexanones; Doxorubicin; Epoxy Compounds; Humans; Leukocytes, Mononuclear; Mice; Multiple Myeloma; NF-kappa B; Osteoclasts; Pyrazines; RANK Ligand; Signal Transduction; Transplantation, Heterologous | 2012 |
A novel NF-kappaB inhibitor DHMEQ selectively targets constitutive NF-kappaB activity and induces apoptosis of multiple myeloma cells in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Benzamides; Calcium-Binding Proteins; CASP8 and FADD-Like Apoptosis Regulating Protein; Caspase 3; Caspase 8; Caspase 9; Caspases; Cell Line, Tumor; Cyclin D; Cyclin D1; Cyclins; Cyclohexanones; Disease Models, Animal; Down-Regulation; Enzyme Activation; Humans; Intracellular Signaling Peptides and Proteins; Membrane Glycoproteins; Mice; Mice, Inbred NOD; Mice, SCID; Multiple Myeloma; Nerve Tissue Proteins; NF-kappa B; Proto-Oncogene Proteins c-bcl-2; Synaptotagmin I; Synaptotagmins; Translocation, Genetic; Vascular Endothelial Growth Factor A | 2005 |
Dehydroxymethylepoxyquinomicin, a novel nuclear factor-kappaB inhibitor, induces apoptosis in multiple myeloma cells in an IkappaBalpha-independent manner.
Topics: Animals; Antineoplastic Agents; Apoptosis; Benzamides; Caspase 3; Caspases; Cyclin D1; Cyclohexanones; Down-Regulation; Drug Screening Assays, Antitumor; Enzyme Activation; Female; Humans; I-kappa B Proteins; Mice; Mice, Inbred ICR; Mice, SCID; Minor Histocompatibility Antigens; Multiple Myeloma; NF-kappa B; NF-KappaB Inhibitor alpha; Proto-Oncogene Proteins c-bcl-2; Tumor Cells, Cultured | 2005 |